BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  FDA

  COVID-19 Update: Pfizer Requests Broad Booster Authorization, Long COVID Questioned

  Pfizer and BioNTech requested the FDA authorize booster shots for their COVID-19 vaccine for all adults 18 years and older, presenting data not available in September.

  November 10, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Biogen Investigates Death of 75-Year-Old on Aduhelm

  The company is investigating the death of a 75-year-old woman who died of ARIA while receiving Aduhelm.

  November 10, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  Global Roundup: Zai Lab Secures Potential Psychiatric Drug For Asian Market

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  November 10, 2021

   · 

  6 min read

   · 

  Alex Keown
• 

  Policy

  Weighing the Risks and Benefits of the COVID-19 Vaccine for Kids

  Between January 4, 2020 and October 30, 2021, COVID-19 accounted for 576 deaths among children 17 and younger, compared to 189 from influenza, according to the CDC.

  November 10, 2021

   · 

  6 min read

   · 

  Gail Dutton
• 

  Bio NC

  UNC and Duke Offer Hope for a Universal Coronavirus Antibody Therapy

  A research team at the University of North Carolina – Chapel Hill (UNC) and Duke University, in Durham, NC identified an antibody that attacks SARS-CoV-2 and its variants and other types of coronaviruses.

  November 10, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Psychedelic Drug Headed to Pivotal Trial in Treatment-Resistant Depression

  The drug for treatment-resistant depression reportedly demonstrated significant improvement in patients at its highest dose of 25 mg. Here’s more about it.

  November 10, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Poseida Goes All-In on Allogeneic CAR-T; Ligand Explores Spin-Off

  Eric Ostertag, CEO of Poseida Therapeutics, believes the future of CAR-T programs is with allogeneic approaches and not autologous.

  November 10, 2021

   · 

  4 min read

   · 

  Alex Keown
• 

  Biotech Bay

  Biotech Companies are Expanding the Frontiers of Engineered Cell Therapy

  Celares and Mission Bio are part of the rapidly evolving push to create and characterize the superhuman powers cells can be endowed with.

  November 10, 2021

   · 

  6 min read

   · 

  Maggie Chen
• 

  Business

  CytoImmune is Cell Therapy Veteran Christina Coughlin’s Next Act

  Cell therapy veteran Christina Coughlin is taking over the reins of the privately-held company developing natural killer immune cells to battle cancer.

  November 10, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  AC Immune Alzheimer’s Drug Reduces Cognitive Decline but Misses Functional Endpoints

  AC Immune’s Phase II Lauriet study of investigational anti-Tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimer’s disease (AD), only met one endpoint.

  November 10, 2021

   · 

  2 min read

   · 

  Heather McKenzie